•
Mar 31, 2022
Viking Therapeutics Q1 2022 Earnings Report
Reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
Key Takeaways
Viking Therapeutics reported a net loss of $16.1 million, or $0.21 per share, for the first quarter ended March 31, 2022. The company's cash balance was $185 million, providing a runway through multiple clinical catalysts.
Phase 2b VOYAGE study evaluating VK2809 for the treatment of NASH continues enrolling patients, with completion of enrollment expected in 2H22.
Phase 1 study of dual GLP-1/GIP agonist VK2735 is ongoing, with results expected by year-end.
A preclinical study supporting Phase 1b VK0214 trial is ongoing, with data submission to the FDA expected in 2Q22.
The company ended the quarter with a cash balance of $185 million.